These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23977453)

  • 1. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).
    Bose P; Grant S
    Leuk Res Rep; 2013 Jan; 2(1):12-14. PubMed ID: 23977453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
    Tibes R; Bogenberger JM
    Front Oncol; 2019; 9():1205. PubMed ID: 31921615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCL-1 is a clinically targetable vulnerability in breast cancer.
    Winder ML; Campbell KJ
    Cell Cycle; 2022 Jul; 21(14):1439-1455. PubMed ID: 35349392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy.
    Kadia TM; Kantarjian HM; Konopleva M
    Oncotarget; 2019 Feb; 10(12):1250-1265. PubMed ID: 30815228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
    Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
    Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.
    Kaufmann SH; Karp JE; Svingen PA; Krajewski S; Burke PJ; Gore SD; Reed JC
    Blood; 1998 Feb; 91(3):991-1000. PubMed ID: 9446661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
    Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y
    Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
    Yamaguchi R; Lartigue L; Perkins G
    Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.
    Glaser SP; Lee EF; Trounson E; Bouillet P; Wei A; Fairlie WD; Izon DJ; Zuber J; Rappaport AR; Herold MJ; Alexander WS; Lowe SW; Robb L; Strasser A
    Genes Dev; 2012 Jan; 26(2):120-5. PubMed ID: 22279045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.
    Liu S; Qiao X; Wu S; Gai Y; Su Y; Edwards H; Wang Y; Lin H; Taub JW; Wang G; Ge Y
    Apoptosis; 2022 Dec; 27(11-12):913-928. PubMed ID: 35943677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
    Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
    Jin L; Tabe Y; Kojima K; Shikami M; Benito J; Ruvolo V; Wang RY; McQueen T; Ciurea SO; Miida T; Andreeff M; Konopleva M
    J Mol Med (Berl); 2013 Dec; 91(12):1383-97. PubMed ID: 23955073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.